Inclusion on the list of medicines reimbursed by National Health Insurance and approved for hospital use.
-
Clinical Benefit
Substantial
The actual benefit of RASILEZ HCT products is substantial.
Clinical Added Value
no clinical added value
RASILEZ HCT 150 mg/12.5 mg, 150 mg/25 mg, 300 mg/12.5 mg and 300 mg/25 mg fixed-dose combinations of aliskiren 150 or 300 mg and hydrochlorothiazide 12.5 or 25 mg provide no improvement in actual benefit (IAB V) in comparison with concurrent use of the two active substances taken separately.
Listen
